Beijing Lideman Biochemical Co., Ltd. (hereinafter referred to as "the Company" or "the Listed Company") is planning to acquire up to 70% of the shares held by certain shareholders of Beijing Xiansheng Xiangrui Bioproducts Co., Ltd. (hereinafter referred to as "the Target Company") for cash (hereinafter referred to as "this transaction"). Prior to this transaction, the Company did not hold any shares in the Target Company; upon completion, the Company will gain control of the Target Company, which will become a subsidiary of the Company. According to preliminary estimates, this transaction is expected to constitute a major asset restructuring as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies." This transaction does not involve the issuance of shares by the listed company, does not constitute a related party transaction, and will not result in a change of control of the Company.
Disclosure of Major Asset Restructuring
On July 30, 2025, the Company signed an "Investment Framework Agreement" with the Target Company and its shareholders, including Shanghai Baijiahui Investment Management Co., Ltd. (renamed to "Hainan Baimai Investment Co., Ltd." on December 24, 2025), Hainan Xiansheng Baijiahui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) regarding matters related to this transaction. For specific details, please refer to the Company's announcement on July 30, 2025, on the Giant Tide Information Network (http://www.cninfo.com.cn) titled "Announcement on Planning Major Asset Restructuring and Signing Investment Framework Agreement" (Announcement No.: 2025-029).